Retinoblastoma pathway–deficient tumor cells (RB-deficient cells)

Retinoblastoma pathway–deficient tumor cells are characterized by the functional loss of the RB1 tumor suppressor protein or its regulatory components, which normally act as the critical gatekeeper for the G1/S phase transition (Burkhart & Sage, 2008, Nature Reviews Cancer). This deficiency leads to uncontrolled cell proliferation and is a hallmark of aggressive malignancies such as small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and osteosarcoma (Knudson, 1971, PNAS). Because the RB protein is the primary downstream effector of CDK4/6, its absence renders these tumor cells inherently resistant to CDK4/6 inhibitors like palbociclib and ribociclib (O'Leary et al., 2018, Nature Communications). However, the loss of RB1 creates unique molecular vulnerabilities, or synthetic lethalities, that can be exploited for therapy. For instance, RB-deficient cells exhibit an increased dependency on mitotic kinases such as Aurora kinase A and PLK1, as well as DNA damage response proteins like CHK1, to maintain genomic stability during rapid division (Gong et al., 2019, Cancer Discovery). Consequently, these cells are the focus of specialized therapeutic strategies aimed at inducing selective apoptosis while sparing RB-intact healthy tissues (Sherr & McCormick, 2002, Cancer Cell). Identification of this deficiency through genomic or proteomic profiling is essential for stratifying patients for these emerging targeted treatments.

Other names

RB1-deficient tumor cellsRB-null cancer cellsRetinoblastoma-deficient cellsRB-deficient phenotypeRB1-negative tumor cells

Synthetic lethality; targeting specific dependencies (e.g., Aurora A, PLK1, CHK1) that arise only in the absence of a functional RB1 pathway to selectively eliminate tumor cells.